Advanced

A Pharmacokinetic and Dosing Study of Intravenous Insulin-Like Growth Factor-I and IGF-Binding Protein-3 Complex to Preterm Infants.

Löfqvist, Chatarina; Niklasson, Aimon; Engström, Eva; Friberg, Lena; Camacho-Hübner, Cecilia; Ley, David LU ; Borg, Jan; Smith, Lois and Hellström, Ann LU (2009) In Pediatric Research 65. p.574-579
Abstract
In preterm infants, low levels of Insulin like growth factor 1 (IGF-I) have been associated with impaired growth and retinopathy of prematurity. Our objective was to study safety and pharmacokinetics of intravenously administered rhIGF-I with its binding protein 3 (rhIGFBP-3) to preterm infants. At 3 days chronological age, an intravenous 3 hours infusion of rhIGF-I/rhIGFBP-3 was administered followed by serial measurements of IGF-I and IGFBP-3. Infants were evaluated for physiological safety measurements. The individual dose of rhIGF-I ranged from 1 to 12 mug/kg. The study was conducted at Queen Silvia Children's Hospital, Gothenburg, Sweden, between January and November 2007. Five patients (3F) with mean (range) PMA 27 weeks (26-29) and... (More)
In preterm infants, low levels of Insulin like growth factor 1 (IGF-I) have been associated with impaired growth and retinopathy of prematurity. Our objective was to study safety and pharmacokinetics of intravenously administered rhIGF-I with its binding protein 3 (rhIGFBP-3) to preterm infants. At 3 days chronological age, an intravenous 3 hours infusion of rhIGF-I/rhIGFBP-3 was administered followed by serial measurements of IGF-I and IGFBP-3. Infants were evaluated for physiological safety measurements. The individual dose of rhIGF-I ranged from 1 to 12 mug/kg. The study was conducted at Queen Silvia Children's Hospital, Gothenburg, Sweden, between January and November 2007. Five patients (3F) with mean (range) PMA 27 weeks (26-29) and birth weight 1022 grams (810-1310) participated. IGF-I and IGFBP-3 levels before infusion were median (range) 18 (12-28) and 771 (651-1047) ng/ml, respectively. Immediately after study drug infusion, serum IGF-I and IGFBP-3 levels were 38 (25-59) and 838 (754-1182) ng/ml, respectively. Median (range) half-life for IGF-I and IGFBP-3 was 0.79 (0.59-1.42) and 0.87 (0.85-0.94) hours, respectively. Blood glucose, insulin, sodium, potassium and physiological safety measures were within normal ranges. The rhIGF-I/rhIGFBP-3 equimolar proportion was effective in increasing serum IGF-I levels and administration under these study conditions was safe and well tolerated. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Pediatric Research
volume
65
pages
574 - 579
publisher
International Pediatric Foundation Inc.
external identifiers
  • wos:000265448700017
  • pmid:19190540
  • scopus:69049098085
ISSN
1530-0447
DOI
10.1203/PDR.0b013e31819d9e8c
language
English
LU publication?
yes
id
0d2a1648-ffa0-48da-adaf-6976cec1aefa (old id 1302918)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19190540?dopt=Abstract
date added to LUP
2009-03-04 16:53:32
date last changed
2017-10-22 04:51:27
@article{0d2a1648-ffa0-48da-adaf-6976cec1aefa,
  abstract     = {In preterm infants, low levels of Insulin like growth factor 1 (IGF-I) have been associated with impaired growth and retinopathy of prematurity. Our objective was to study safety and pharmacokinetics of intravenously administered rhIGF-I with its binding protein 3 (rhIGFBP-3) to preterm infants. At 3 days chronological age, an intravenous 3 hours infusion of rhIGF-I/rhIGFBP-3 was administered followed by serial measurements of IGF-I and IGFBP-3. Infants were evaluated for physiological safety measurements. The individual dose of rhIGF-I ranged from 1 to 12 mug/kg. The study was conducted at Queen Silvia Children's Hospital, Gothenburg, Sweden, between January and November 2007. Five patients (3F) with mean (range) PMA 27 weeks (26-29) and birth weight 1022 grams (810-1310) participated. IGF-I and IGFBP-3 levels before infusion were median (range) 18 (12-28) and 771 (651-1047) ng/ml, respectively. Immediately after study drug infusion, serum IGF-I and IGFBP-3 levels were 38 (25-59) and 838 (754-1182) ng/ml, respectively. Median (range) half-life for IGF-I and IGFBP-3 was 0.79 (0.59-1.42) and 0.87 (0.85-0.94) hours, respectively. Blood glucose, insulin, sodium, potassium and physiological safety measures were within normal ranges. The rhIGF-I/rhIGFBP-3 equimolar proportion was effective in increasing serum IGF-I levels and administration under these study conditions was safe and well tolerated.},
  author       = {Löfqvist, Chatarina and Niklasson, Aimon and Engström, Eva and Friberg, Lena and Camacho-Hübner, Cecilia and Ley, David and Borg, Jan and Smith, Lois and Hellström, Ann},
  issn         = {1530-0447},
  language     = {eng},
  pages        = {574--579},
  publisher    = {International Pediatric Foundation Inc.},
  series       = {Pediatric Research},
  title        = {A Pharmacokinetic and Dosing Study of Intravenous Insulin-Like Growth Factor-I and IGF-Binding Protein-3 Complex to Preterm Infants.},
  url          = {http://dx.doi.org/10.1203/PDR.0b013e31819d9e8c},
  volume       = {65},
  year         = {2009},
}